Key Highlights
- Oxford Nanopore Technologies plc (LSE:ONT) fell 8.98% on 8 October 2026 after closing at 220.60p on Wednesday.
- The shares had roughly doubled from July lows near 107p and touched about 217p to 220p in recent sessions, setting up heavy profit-taking.
- Major backer IP Group sold 10 million shares for about £21 million on 2 October, keeping a 7.23% stake under a 90-day lock-in.
- Rising bond yields and a weaker session for healthcare and biotech stocks added pressure on the FTSE 250 constituent.
- The company won a preliminary injunction against MGI Tech GmbH in September, with a Patent trial against MGI set for 2027.
Oxford Nanopore Gives Back Part of Its Rally
Shares in Oxford Nanopore Technologies plc (LSE:ONT), the Oxford-based developer of nanopore DNA and RNA sequencing technology, fell 8.98% on Thursday 8 October 2026. The stock had closed at 220.60p on Wednesday, near the top of its 52-week range of 95.61p to 238.80p, before sellers took control.
The fall followed one of the strongest runs in the FTSE 250 this year. The shares roughly doubled from lows around 107p in July. In late September, LSE:ONT climbed from about 182p to more than 217p over two sessions, and trading volumes spiked to nearly 15 million shares in a single day. A move of that size often invites profit-taking, especially when the wider market turns defensive.
Key Reasons Why LSE:ONT Fell
Profit-taking was the main factor. After such a sharp rally, many short-term traders and some long-term holders chose to lock in gains. The analyst consensus target price of around 199p sits below where the shares were trading before Thursday, which gave some investors a reason to trim positions.
Supply from a major Shareholder also played a role. On 2 October, IP Group, one of the company's founding investors, completed the sale of 10 million Oxford Nanopore shares for about £21 million, or roughly 210p per share. IP Group still holds 70,775,255 shares, or 7.23% of the company, and has agreed a 90-day lock-in on that stake. Funds managed by IP Group hold another 11.8 million shares. While the sale was modest, it signalled that early backers are willing to realise value at current levels.
Macro conditions turned hostile for growth stocks. Brent Crude rose above $104 a barrel, gilt and Treasury yields stayed near multi-year highs, and Federal Reserve minutes pointed to another possible rate rise. Loss-making growth companies such as LSE:ONT are valued on future cash flows, so higher discount rates tend to hit them hardest. US healthcare shares also opened weaker on Thursday, adding to pressure on life science tools names.
Why Investors Are Watching Oxford Nanopore
Oxford Nanopore remains one of the most closely followed UK life science stocks. Its sequencing platforms can read long strands of DNA and RNA in real time, from portable devices to large PromethION systems used for population-scale studies. The company is pushing further into clinical, biopharma and applied industrial markets beyond its traditional research customer base.
In March 2026, the company cut its medium-term Revenue growth target to between 21% and 25% at constant currency for 2026 and 2027, down from above 30%, citing US National Institutes of Health budget pressure and a tough China market. The shares fell sharply at the time, and a new chief executive was named. The rebound since July shows that investors have regained confidence in the plan, helped by guidance for a gross Margin of around 62% in 2026 and operating cost growth of just 0% to 5% after two rounds of restructuring in 2025.
Legal progress has also drawn attention. On 16 September, Oxford Nanopore secured a preliminary injunction against MGI Tech GmbH. The company has patent proceedings against MGI, with a trial set for 2027, and High Court proceedings alleging trade secret misappropriation and breach of contract against MGI and BGI entities. Success in these cases could protect its market position in Europe.
What Comes Next for LSE:ONT
Investors will look for signs that revenue growth is holding within guidance during the second half, along with continued progress on margins and cash burn. Any update on clinical adoption, new product launches or the MGI litigation could move the stock. Takeover speculation has surfaced in the past, with the company described as potentially attractive to large diagnostics groups, and that theme often resurfaces when the shares move sharply.
For now, the 8.98% fall looks more like a cooling of an overheated rally than a change in the company's story. Oxford Nanopore Technologies (LSE:ONT) remains a high-volatility FTSE 250 stock where sentiment, interest rates and sector flows can drive large daily swings.






Please wait processing your request...